Needham Reiterates Buy on Glaukos Corporation with $150 Price Target
Needham maintains its buy rating on Glaukos, setting a price target of $150, a 13.90% upside from the current price.
Key Points
- Needham reiterated its buy rating on Glaukos Corporation, setting a price target of $150 on June 17, 2026.
- Needham's $150 price target implies 13.90% upside from Glaukos Corporation's ($GKOS) current $131.69 share price.
- Shares of Glaukos traded near $130.14, with a market cap of $7.49 billion and a forward P/E of 287.47.
- Insiders recently bought shares, and other analysts like Citigroup and BTIG also maintain buy ratings with targets around $162.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Needham reiterated its buy rating for Glaukos Corporation (NYSE: GKOS), setting a price target of $150. The analyst, David Saxon, continues to show confidence in the company's outlook. Shares of Glaukos are currently trading around $130.14.
Glaukos Corporation Stock Down 26.8%
Shares of Glaukos are trading near $130.14. The company boasts a market capitalization of about $7.49 billion and has a forward P/E ratio of 287.47. The stock's 52-week range spans from $73.16 to $148.11, with a 50-day moving average of $125.42 and a 200-day moving average of $107.46. Glaukos has a beta of 0.815, indicating lower volatility compared to the broader market. The company maintains a strong liquidity position with a current ratio of 5.43 and a quick ratio of 4.43, while its debt-to-equity ratio stands at 15.78.
$GKOS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Glaukos reported revenue of approximately $551.35 million, showing a growth rate of 41.2%. Despite this, the company posted a net margin of -34.34% and a return on equity of -26.39%, reflecting ongoing challenges in profitability. The next earnings report is expected on July 29, 2026.
Insider Buying and Selling at Glaukos Corporation
On May 28, 2026, several insiders, including Marc Stapley, Denice Torres, Leana Wen, Mark Foley, and Aimee Weisner, purchased shares in the company. Each insider bought between 1,878 and 2,987 shares. These transactions were not part of any planned trading program, suggesting confidence in the company's future.
Analysts Set New Price Targets
On June 17, 2026, Needham maintained its buy rating on Glaukos with a $150 price target. Other firms like Citigroup and BTIG also reiterated their buy ratings earlier in June, each setting a target of $162. Overall, the consensus among 12 analysts rates the stock as a strong buy, with a mean target price of $156.33.
About Glaukos Corporation
Glaukos Corporation, headquartered in Aliso Viejo, California, is a healthcare company specializing in medical devices. It focuses on developing therapies for glaucoma, corneal disorders, and retinal diseases. Glaukos' product lineup includes micro-bypass stents like the iStent and iStent inject W, designed to treat open-angle glaucoma. The company also offers the iDose TR for reducing intraocular pressure and develops solutions for retinal diseases and keratoconus. Founded in 1998, Glaukos sells its products through direct sales and distributors to medical facilities worldwide.
Bottom Line
Needham's reiteration of a buy rating with a $150 target reflects continued optimism about Glaukos' potential. The stock is trading near $130.14, with a high forward P/E ratio indicating expectations for future growth. Insider buying further supports confidence in the company's trajectory. Investors should note that analyst ratings and targets are based on current assessments and may change.
Get Glaukos Corporation alerts
New 13F filings, insider trades, and analyst moves on $GKOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.